FILE 'REGISTRY' ENTERED AT 14:55:22 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5
DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s .c.....c./sqsp and sql<28
3698 .C.....C./SQSP
1892821 SQL<28
L7 3698 .C.....C./SQSP AND SQL<28

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 31.52 706.62

FILE 'BIOSIS' ENTERED AT 14:56:21 ON 30 JAN 2003

FILE 'MEDLINE' ENTERED AT 14:56:21 ON 30 JAN 2003

FILE 'CAPLUS' ENTERED AT 14:56:21 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'EMBASE' ENTERED AT 14:56:21 ON 30 JAN 2003

FILE 'SCISEARCH' ENTERED AT 14:56:21 ON 30 JAN 2003

FILE 'PCTFULL' ENTERED AT 14:56:21 ON 30 JAN 2003

FILE 'USPATFULL' ENTERED AT 14:56:21 ON 30 JAN 2003

FILE 'USPAT2' ENTERED AT 14:56:21 ON 30 JAN 2003

FILE 'EUROPATFULL' ENTERED AT 14:56:21 ON 30 JAN 2003

=> s l8 and (factor)
L9 623 L8 AND (FACTOR)

=> s l9 and (Vii or viia or xa)
L10 90 L9 AND (VII OR VIIA OR XA)

=> s l13 and py<=2000
2 FILES SEARCHED...
5 FILES SEARCHED...
L14 11 L13 AND PY<=2000

=> d l14 py pi in au ti so ab

L14 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS
PY 1997
AU Orning, Lars; Stephens, Ross W.; Petersen, Lizette B.; Hamers, Maria J.A.G.; Stormorken, Helge; Sakariassen, Kjell S.
TI A peptide sequence from the EGF-2 like domain of FVII inhibits TF-dependent FX activation
SO Thrombosis Research (1997), 86(1), 57-67
CODEN: THBRAA; ISSN: 0049-3848
AB The authors have found that synthetic peptides derived from the two epidermal growth factor-like domains of factor VII are inhibitors of tissue factor dependent factor X activation. Inhibition was most pronounced for a constrained sequence of amino acids corresponding to positions 91-102 of factor VII, Cys-Val-Asn-Glu-Asn-Gly-Gly-Cys-Glu-Gln-Tyr-Cys. The biol. activity appeared to be localized to the tripeptide "motif", Glu-Gln-Tyr, within the larger sequence. The cyclic peptide was also an inhibitor of tissue factor induced coagulation of plasma, using lipidated tissue factor or tissue factor expressed on the surface of living cells. However, it did not interfere with intrinsic coagulation. Inhibition of factor X activation was dose-dependent with an IC50 value of 350 .mu.M. Kinetic analyses revealed non-competitive inhibition with respect to factor X and suggested that the peptide sequence interferes with the factor VII/tissue factor/factor X complex formation and function. A pentapeptide analog of the putative pharmacophore was also a dose-dependent inhibitor of factor X activation with an IC50 value of 560 .mu.M, but the tripeptide, Glu-Gln-Tyr, alone was without effect. The authors' results suggest a direct role for the second epidermal growth factor-like domain of factor VII, and in particular its loop I, in the formation and function of the factor VII / tissue factor / factor X complex.

=> d l14 py pi in au ti so ab 2-11

L14 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS
PY 1995
1995
1995
PATENT NO. KIND DATE APPLICATION NO. DATE
--- --- --- --- ---
PI WO 9500847 A1 19950105 WO 1994-GB1314 19940617 <--
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9469754 A1 19950117 AU 1994-69754 19940617 <--
ZA 9404336 A 19950227 ZA 1994-4336 19940617 <--

IN Stephens, Ross Wentworth; Oerning, Lars; Sakariassen, Kjell
IN Stephens, Ross Wentworth; Oerning, Lars; Sakariassen, Kjell
TI Immunoassay
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
AB The present invention relates to an assay for the formation of multi-protein complexes (e.g., factor VII-tissue factor complex) in, e.g., body fluids by the steps of: (1) reacting a first protein of a multi-protein complex with an immobilized first antibody specific therefor which does not interfere with complex formation; (2) optionally adding further proteins which form part of the multi-protein complex; (3) optionally adding a test substance; (4) adding the remaining protein(s) required for formation of the multi-protein complex; (5) adding a labeled second antibody specific to a protein added in step (4); and (6) detecting and optionally detg. the amt. of the second antibody immobilized as an indication of multi-protein complex formation. Such an assay can be used to det. whether or to what degree a naturally produced multi-protein complex is formed by an individual. In this way any malfunction in formation of a multi-protein complex, for example due to a genetic disorder or physiol. disturbance can be ascertained. Examples are given of the detn. of the multi-protein complex factor VII-tissue factor by ELISA and use of this assay to analyze human blood plasma.

L14 ANSWER 3 OF 11 USPATFULL
PI US 6228837 B1 20010508
WO 9509180 19950406 <--
IN Stern, David M., Great Neck, NY, United States
Clauss, Matthias, Bad Nauheim, Germany, Federal Republic of
Kao, Janet, New York, NY, United States
Kayton, Mark, New York, NY, United States
Libutti, Steven K., Fort Lee, NJ, United States
IN Stern, David M., Great Neck, NY, United States
Clauss, Matthias, Bad Nauheim, Germany, Federal Republic of
Kao, Janet, New York, NY, United States
Kayton, Mark, New York, NY, United States
Libutti, Steven K., Fort Lee, NJ, United States
TI Endothelial monocyte activating polypeptide II: a mediator which activates host response
AB This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).

L14 ANSWER 4 OF 11 USPATFULL
PI US 6083913 20000704 <--
WO 9640750 19961219 <--
IN Dower, William J., Menlo Park, CA, United States
Barrett, Ronald W., Saratoga, CA, United States
Cwirla, Steven E., Menlo Park, CA, United States
Duffin, David J., East Palo Alto, CA, United States
Gates, Christian M., Morgan Hill, CA, United States
Haselden, Sherril S., Santa Cruz, CA, United States
Mattheakis, Larry C., Cupertino, CA, United States
Schatz, Peter J., Mountain View, CA, United States
Wagstrom, Christopher R., Los Altos, CA, United States
Wrighton, Nicholas C., Palo Alto, CA, United States

IN Dower, William J., Menlo Park, CA, United States
Barrett, Ronald W., Saratoga, CA, United States
Cwirla, Steven E., Menlo Park, CA, United States
Duffin, David J., East Palo Alto, CA, United States
Gates, Christian M., Morgan Hill, CA, United States
Haselden, Sherril S., Santa Cruz, CA, United States
Mattheakis, Larry C., Cupertino, CA, United States
Schatz, Peter J., Mountain View, CA, United States
Wagstrom, Christopher R., Los Altos, CA, United States
Wrighton, Nicholas C., Palo Alto, CA, United States
TI Peptides and compounds that bind to a thrombopoietin receptor
AB Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

L14 ANSWER 5 OF 11 USPATFULL
PI US 6057287 20000502 <--
IN Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States
IN Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States
TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof
AB This invention relates to Kunitz domain proteins that bind to, and preferably inhibit, one or more kallikreins, and to therapeutic, diagnostic, and purification use of these proteins.

L14 ANSWER 6 OF 11 USPATFULL
PI US 6034212 20000307 <--
IN Sudol, Marius, New York, NY, United States
Bork, Peer, Heidelberg, Germany, Federal Republic of
Chen, Henry, New York, NY, United States
IN Sudol, Marius, New York, NY, United States
Bork, Peer, Heidelberg, Germany, Federal Republic of
Chen, Henry, New York, NY, United States
TI SH3 kinase domain associated protein, a signalling domain therein, nucleic acids encoding the protein and the domain, and diagnostic and therapeutic uses thereof
AB The present invention relates to regulation and control of cellular processes by SH3-domain binding proteins, by putative signalling domains of such proteins, ligands of the signalling domain, and diagnosis and therapy based on the activity of such proteins, signalling domains, and ligands.

L14 ANSWER 7 OF 11 USPATFULL
PI US 5891664 19990406 <--
IN Dan.o slashed. , Keld, Charlottenlund, Denmark
Blasi, Francesco, Charlottenlund, Denmark
Roldan, Ann Louring, Vallensb.ae butted.k, Denmark
Cubellis, Maria Vittoria, Napoli, Italy
Masucci, Maria Teresa, Napoli, Italy
Appella, Ettore, Chevy Chase, MD, United States
Schleuning, Wolf-Dieter, Berlin, Germany, Federal Republic of
Behrendt, Niels, Bagsv.ae butted.rd, Denmark
R.o slashed.nne, Ebbe, Copenhagen, Denmark
Kristensen, Peter, Copenhagen, Denmark
Pollanen, Jari, Espoo, Finland
Salonen, Eeva-Marjatta, Espoo, Finland
Stephens, Ross W., Helsinki, Finland
Tapiovaara, Hannele, Helsinki, Finland

Vaheri, Antti, Kauniainen, Finland
M.o slashed.ller, Lisbeth Birk, Bagsv.ae butted.rd, Denmark
Ellis, Vincent, Copenhagen, Denmark
Lund, Leif R.o slashed.ge, Copenhagen, Denmark
Ploug, Michael, Copenhagen, Denmark
Pyke, Charles, S.o slashed.borg, Denmark
Patthy, Laszlo, Budapest, Hungary

IN Dan.o slashed. , Keld, Charlottenlund, Denmark
Blasi, Francesco, Charlottenlund, Denmark
Roldan, Ann Louring, Vallensb.ae butted.k, Denmark
Cubellis, Maria Vittoria, Napoli, Italy
Masucci, Maria Teresa, Napoli, Italy
Appella, Ettore, Chevy Chase, MD, United States
Schleuning, Wolf-Dieter, Berlin, Germany, Federal Republic of
Behrendt, Niels, Bagsv.ae butted.rd, Denmark
R.o slashed.nne, Ebbe, Copenhagen, Denmark
Kristensen, Peter, Copenhagen, Denmark
Pollanen, Jari, Espoo, Finland
Salonen, Eeva-Marjatta, Espoo, Finland
Stephens, Ross W., Helsinki, Finland
Tapiovaara, Hannele, Helsinki, Finland
Vaheri, Antti, Kauniainen, Finland
M.o slashed.ller, Lisbeth Birk, Bagsv.ae butted.rd, Denmark
Ellis, Vincent, Copenhagen, Denmark
Lund, Leif R.o slashed.ge, Copenhagen, Denmark
Ploug, Michael, Copenhagen, Denmark
Pyke, Charles, S.o slashed.borg, Denmark
Patthy, Laszlo, Budapest, Hungary

TI Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)

AB Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

L14 ANSWER 8 OF 11 USPATFULL

PI US 5710126 19980120 <--

IN Griffith, Irwin J., North Reading, MA, United States
Kuo, Mei-chang, Winchester, MA, United States
Luqman, Mohammad, Waltham, MA, United States

IN Griffith, Irwin J., North Reading, MA, United States
Kuo, Mei-chang, Winchester, MA, United States
Luqman, Mohammad, Waltham, MA, United States

TI T cell epitopes of ryegrass pollen allergen

AB The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of Lol p V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or diagnosis of sensitivity to Lol p V or an allergen immunologically related to Lol p V in an individual. Therapeutic compositions comprising one or more peptides of the invention are also provided.

L14 ANSWER 9 OF 11 USPATFULL

PI US 5683983 19971104 <--
IN Barrett, Ronald W., Sunnyvale, CA, United States
England, Bruce P., Fremont, CA, United States
Schatz, Peter J., Mountain View, CA, United States
Sloan, Derek, Los Gatos, CA, United States
Chen, Min-Jia, San Francisco, CA, United States
IN Barrett, Ronald W., Sunnyvale, CA, United States
England, Bruce P., Fremont, CA, United States
Schatz, Peter J., Mountain View, CA, United States
Sloan, Derek, Los Gatos, CA, United States
Chen, Min-Jia, San Francisco, CA, United States
TI Peptides and compounds that bind to the IL-5 receptor
AB Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.

L14 ANSWER 10 OF 11 USPATFULL
PI US 5677280 19971014 <--
IN Barrett, Ronald W., Saratoga, CA, United States
England, Bruce P., Fremont, CA, United States
Schatz, Peter J., Mountain View, CA, United States
Sloan, Derek, Los Gatos, CA, United States
Chen, Min-Jia, San Francisco, CA, United States
IN Barrett, Ronald W., Saratoga, CA, United States
England, Bruce P., Fremont, CA, United States
Schatz, Peter J., Mountain View, CA, United States
Sloan, Derek, Los Gatos, CA, United States
Chen, Min-Jia, San Francisco, CA, United States
TI Peptides and compounds that bind to the IL-5 receptor
AB Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.

L14 ANSWER 11 OF 11 USPATFULL
PI US 5583111 19961210 <--
WO 9426777 19941124 <--
IN Hemberger, J urgen, Aschaffenburg, Germany, Federal Republic of
Sawyer, Roy, Dyfed, Germany, Federal Republic of
Wolf, Sabine, Otzberg, Germany, Federal Republic of
Dodt, Johannes, Recklinghausen, Germany, Federal Republic of
IN Hemberger, J urgen, Aschaffenburg, Germany, Federal Republic of
Sawyer, Roy, Dyfed, Germany, Federal Republic of
Wolf, Sabine, Otzberg, Germany, Federal Republic of
Dodt, Johannes, Recklinghausen, Germany, Federal Republic of
TI Thrombin inhibitors
AB The invention relates to novel polypeptides with antithrombin activity obtainable from extracts of tissues or secretions of leeches of the order Rhynchobdellida, particularly of the species Theromyzon tessulatum. The polypetides have molecular weights of about 14 kD, 9 kD and 3 kD and can be used in pharmaceutical compositions for the treatment of thrombosis related disorders and events.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	444.15	1150.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

STN INTERNATIONAL LOGOFF AT 15:07:06 ON 30 JAN 2003